Company Overview and News

 
KLCI to take cue from global markets, struggle to defend 1,800-point level

2018-08-12 theedgemarkets
KUALA LUMPUR (Aug 13): The FBM KLCI is seen starting the week on a flat note and struggle to defend the 1,800-point level, tracking the weaker close at most global markets last Friday.
7223 7168 7027 0082 5246 9695 5025 5014 CIMDF 1023 5754 4995 7219 MYPRY

 
MSC, Westports, YFG, Marine & General, NWP, Minetech, GPacket, MAHB, PRG, CIMB Group, Utusan Melayu, Versatile Creative and Petrol One Resources

2018-08-11 theedgemarkets
KUALA LUMPUR (Aug 10): Based on corporate announcements and news flow today, stocks in focus on Monday may include the following: Malaysia Smelting Corp Bhd, Westports Holdings Bhd, YFG Bhd, Marine & General Bhd, NWP Holdings Bhd, Minetech Resources Bhd, Green Packet Bhd, Malaysia Airports Holdings Bhd, PRG Holdings Bhd, CIMB Group Holdings Bhd, Utusan Melayu (Malaysia) Bhd, Versatile Creative Bhd, PLS Plantations Bhd, Petrol One Resources Bhd and Jadi Imaging Holdings Bhd.
7223 7168 7027 0082 5246 9695 7099 5025 5014 CIMDF 1023 5754 4995 7219 MYPRY

 
NWP aborts RM745m housing contract due to lack of progress

2018-08-10 theedgemarkets
KUALA LUMPUR (Aug 10): NWP Holdings Bhd said today it has decided to abort a RM744.96 million contract to construct affordable housing under six projects of SPNB Aspirasi Sdn Bhd and Perbadanan PRIMA Malaysia, due to the lack of progress made in negotiations.
BSMAF 5025 1818

 
NWP fell almost 30% over termination of a joint development in China

2018-05-31 thestar.com.my
KUALA LUMPUR: NWP Holdings Bhd shares fell almost 30% after has mutually terminated a joint development deal in China with LBS Bina Group Bhd .
5789 5025

6
Trading ideas: IHH Healthcare, Kelington, NWP, Salcon

2018-04-17 thestar.com.my
KUALA LUMPUR: JF Apex Research expects IHH Healthcare Bhd , Kelington Group Bhd , NWP Holdings Bhd and Salcon Bhd to generate trading interest following their latest corporate news.
5225 FORTIS Q0F 0151 5025 IHHHF 532843

 
NWP shares rise after acquisition is terminated

2018-04-17 thestar.com.my
KUALA LUMPUR: NWP Holdings Bhd rose almost 4% this morning after announcing its plans to abort plans the acquisition of a 30% stake in US-incorporated Aviation AI Inc (AAI).
5025

4
NWP terminates share sale deal

2018-04-16 thestar.com.my
PETALING JAYA: Timber firm NWP Holdings Bhd has terminated the share sale agreement with regard to a 30% equity interest acquisition in Aviation A.I. Inc (AAI).
BSMAF 5025 1818

14
Bursa Malaysia eases on nervousness over direction of us economic, foreign policies

2018-03-15 themalaymailonline
KUALA LUMPUR, March 15 — Bursa Malaysia closed at an intra-day low today on nervousness over the direction of US economic and foreign policies, leaving the local bourse in the red throughout the day, dealers said.
PBLOF 5225 Q0F 1295 BSMAF 1481 5025 IHHHF 1818

15
Bursa ends lower on rampant profit-taking

2018-03-14 themalaymailonline
KUALA LUMPUR, March 14 — Bursa Malaysia closed lower today, echoing global and regional equity performances on rampant profit-taking, leaving the indices in the red throughout the day, dealers said.
5238 PNADF PBLOF 1295 BSMAF 5025 PNAGF 6033 0152 1818

8
Bursa in the red at mid-afternoon

2018-03-13 themalaymailonline
KUALA LUMPUR, March 13 — Bursa Malaysia remained in the red at mid-afternoon today as traders increased profit-taking activities, capitalising on yesterday's substantial gains, dealers said.
PBLOF 1295 BSMAF 5025 1818

8
KL shares still down at mid-morning

2018-03-13 themalaymailonline
KUALA LUMPUR, March 13 — Shares on Bursa Malaysia remained in the red at mid-morning today with traders still affected by the mixed overnight performance of Wall Street and as domestic traders offload shares from yesterday's gains.
1201 PBLOF 1295 BSMAF 5025 1818

10
Bursa Malaysia ends higher on escalating demand

2018-03-12 themalaymailonline
KUALA LUMPUR, March 12 — Bursa Malaysia closed higher today on the back of continued escalating demand, with traders active throughout the day and registering positives across the board in trying to obtain bargains, dealers said.
PBLOF 1295 BSMAF 5025 HIPEF 1818 5199

8
Bursa stays positive at mid-afternoon

2018-03-12 themalaymailonline
KUALA LUMPUR, March 12 — Bursa Malaysia remained in positive territory at mid-afternoon today with all indices recording gains, taking the cue from last week’s firm trading, dealers said.
PBLOF 1295 BSMAF 0096 5025 1818

8
Bursa Malaysia ends morning session higher

2018-03-12 themalaymailonline
KUALA LUMPUR, March 12 — Shares on Bursa Malaysia ended the morning session higher in line with regional peers and amid optimism among traders in scouring for bargains.
PBLOF 1295 BSMAF 5025 1818

8
KL shares higher at mid-morning

2018-03-12 themalaymailonline
KUALA LUMPUR, March 12 — Shares on Bursa Malaysia remained higher at mid-morning today as traders took advantage of positive and encouraging micro and macro-economic environment, as it propelled buying momentum among traders.
PBLOF 1295 BSMAF 5025 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...